Current pharmacologic therapies and emerging alternatives in the treatment of ulcerative colitis

Tetsuya Nakamura, Masakazu Nagahori, Takanori Kanai, Mamoru Watanabe

研究成果: Article

4 引用 (Scopus)

抄録

Recent progress in both basic and clinical research has led us to develop sophisticated and effective medical therapy of ulcerative colitis (UC). Although classical agents such as aminosalicylates, corticosteroids and immunomodulatory drugs have remained as the gold standard for decades, their novel formulations and/or dosage regimens have changed their placements in the medical management of UC. In addition, studies have shown that a number of novel therapeutic agents, designed to target specific mechanisms involved in the inflammatory cascade, have efficacy for the treatment of UC and they will have significant clinical impacts in the near future. A clear understanding of the proven and potential benefits of both the standard and emerging therapies will be required for the optimum individual care of patients with varied clinical presentations.

元の言語English
ページ(範囲)36-41
ページ数6
ジャーナルDigestion
77
発行部数SUPPL. 1
DOI
出版物ステータスPublished - 2008 1
外部発表Yes

Fingerprint

Complementary Therapies
Ulcerative Colitis
Patient Care
Adrenal Cortex Hormones
Therapeutics
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Gastroenterology

これを引用

Current pharmacologic therapies and emerging alternatives in the treatment of ulcerative colitis. / Nakamura, Tetsuya; Nagahori, Masakazu; Kanai, Takanori; Watanabe, Mamoru.

:: Digestion, 巻 77, 番号 SUPPL. 1, 01.2008, p. 36-41.

研究成果: Article

Nakamura, Tetsuya ; Nagahori, Masakazu ; Kanai, Takanori ; Watanabe, Mamoru. / Current pharmacologic therapies and emerging alternatives in the treatment of ulcerative colitis. :: Digestion. 2008 ; 巻 77, 番号 SUPPL. 1. pp. 36-41.
@article{54bae61d37b641a69597f94f7c49dc46,
title = "Current pharmacologic therapies and emerging alternatives in the treatment of ulcerative colitis",
abstract = "Recent progress in both basic and clinical research has led us to develop sophisticated and effective medical therapy of ulcerative colitis (UC). Although classical agents such as aminosalicylates, corticosteroids and immunomodulatory drugs have remained as the gold standard for decades, their novel formulations and/or dosage regimens have changed their placements in the medical management of UC. In addition, studies have shown that a number of novel therapeutic agents, designed to target specific mechanisms involved in the inflammatory cascade, have efficacy for the treatment of UC and they will have significant clinical impacts in the near future. A clear understanding of the proven and potential benefits of both the standard and emerging therapies will be required for the optimum individual care of patients with varied clinical presentations.",
keywords = "Aminosalicylates, Biologic therapy, Corticosteroids, Immunosuppressants, Ulcerative colitis",
author = "Tetsuya Nakamura and Masakazu Nagahori and Takanori Kanai and Mamoru Watanabe",
year = "2008",
month = "1",
doi = "10.1159/000111486",
language = "English",
volume = "77",
pages = "36--41",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Current pharmacologic therapies and emerging alternatives in the treatment of ulcerative colitis

AU - Nakamura, Tetsuya

AU - Nagahori, Masakazu

AU - Kanai, Takanori

AU - Watanabe, Mamoru

PY - 2008/1

Y1 - 2008/1

N2 - Recent progress in both basic and clinical research has led us to develop sophisticated and effective medical therapy of ulcerative colitis (UC). Although classical agents such as aminosalicylates, corticosteroids and immunomodulatory drugs have remained as the gold standard for decades, their novel formulations and/or dosage regimens have changed their placements in the medical management of UC. In addition, studies have shown that a number of novel therapeutic agents, designed to target specific mechanisms involved in the inflammatory cascade, have efficacy for the treatment of UC and they will have significant clinical impacts in the near future. A clear understanding of the proven and potential benefits of both the standard and emerging therapies will be required for the optimum individual care of patients with varied clinical presentations.

AB - Recent progress in both basic and clinical research has led us to develop sophisticated and effective medical therapy of ulcerative colitis (UC). Although classical agents such as aminosalicylates, corticosteroids and immunomodulatory drugs have remained as the gold standard for decades, their novel formulations and/or dosage regimens have changed their placements in the medical management of UC. In addition, studies have shown that a number of novel therapeutic agents, designed to target specific mechanisms involved in the inflammatory cascade, have efficacy for the treatment of UC and they will have significant clinical impacts in the near future. A clear understanding of the proven and potential benefits of both the standard and emerging therapies will be required for the optimum individual care of patients with varied clinical presentations.

KW - Aminosalicylates

KW - Biologic therapy

KW - Corticosteroids

KW - Immunosuppressants

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=40949126191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949126191&partnerID=8YFLogxK

U2 - 10.1159/000111486

DO - 10.1159/000111486

M3 - Article

C2 - 18204260

AN - SCOPUS:40949126191

VL - 77

SP - 36

EP - 41

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - SUPPL. 1

ER -